1
|
Cripe TP, Roberts RD, Chandler DS, Setty BA, Chen S, Shenoy A, Venkataramany AS, Ringwalt EM, Scharschmidt T, Utset-Ward T, Konieczkowski DJ, Grignol VP, Beane JD, Ruff SM, Pollock RE. Progress in sarcomas: Highlights from the 2023 annual meetingof the Connective Tissue Oncology Society. Mol Ther Oncol 2024; 32:200779. [PMID: 38596308 PMCID: PMC10915594 DOI: 10.1016/j.omton.2024.200779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 04/11/2024]
Affiliation(s)
- Timothy P. Cripe
- Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, USA
- Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, The Ohio State University, Columbus, OH, USA
| | - Ryan D. Roberts
- Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, USA
- Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, The Ohio State University, Columbus, OH, USA
| | - Dawn S. Chandler
- Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, USA
| | - Bhuvana A. Setty
- Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, The Ohio State University, Columbus, OH, USA
| | - Sonja Chen
- Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital, Columbus, OH, USA
| | - Archana Shenoy
- Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital, Columbus, OH, USA
| | - Akila S. Venkataramany
- Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, USA
- Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH, USA
- Medical Scientist Training Program, The Ohio State University, Columbus, OH, USA
- Center for RNA Biology, The Ohio State University, Columbus, OH, USA
| | - Emily M. Ringwalt
- Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, USA
- Molecular, Cellular, and Developmental Biology Graduate Program, The Ohio State University, Columbus, OH, USA
| | - Thomas Scharschmidt
- Department of Orthopaedic Surgery, Nationwide Children’s Hospital, Columbus, OH, USA
| | - Thomas Utset-Ward
- Department of Orthopaedic Surgery, Nationwide Children’s Hospital, Columbus, OH, USA
| | | | - Valerie P. Grignol
- Department of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Joel D. Beane
- Department of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Samantha M. Ruff
- Department of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - Raphael E. Pollock
- Department of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA
| |
Collapse
|
2
|
Ringwalt EM, Currier MA, Glaspell AM, Chen CY, Cannon MV, Cam M, Gross AC, Gust M, Wang PY, Boon L, Biederman LE, Schwarz E, Rajappa P, Lee DA, Mardis ER, Carson WE, Roberts RD, Cripe TP. Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma. bioRxiv 2024:2024.03.02.582994. [PMID: 38464161 PMCID: PMC10925327 DOI: 10.1101/2024.03.02.582994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/12/2024]
Abstract
We previously reported that the DNA alkylator and transcriptional-blocking chemotherapeutic agent trabectedin enhances oncolytic herpes simplex viroimmunotherapy in human sarcoma xenograft models, though the mechanism remained to be elucidated. Here we report trabectedin disrupts the intrinsic cellular anti-viral response which increases viral transcript spread throughout the human tumor cells. We also extended our synergy findings to syngeneic murine sarcoma models, which are poorly susceptible to virus infection. In the absence of robust virus replication, we found trabectedin enhanced viroimmunotherapy efficacy by reducing immunosuppressive macrophages and stimulating granzyme expression in infiltrating T and NK cells to cause immune-mediated tumor regressions. Thus, trabectedin enhances both the direct virus-mediated killing of tumor cells and the viral-induced activation of cytotoxic effector lymphocytes to cause tumor regressions across models. Our data provide a strong rationale for clinical translation as both mechanisms should be simultaneously active in human patients.
Collapse
|